Forward Pharma is a Danish biopharmaceutical company that has developed a proprietary formulation of dimethyl fumarate (DMF) aimed at treating various inflammatory and neurological conditions. This formulation is significant in the context of diseases such as multiple sclerosis, where DMF has been shown to have therapeutic effects. The company’s innovative approach to drug formulation and its focus on addressing unmet medical needs in the pharmaceutical landscape highlight its commitment to advancing treatment options for patients suffering from chronic conditions.

In addition to its proprietary formulation, Forward Pharma has engaged in strategic partnerships to enhance its research and development capabilities. Notably, the company entered into a License Agreement with Biogen, granting them an irrevocable license to its intellectual property. This collaboration not only provided Forward Pharma with a substantial non-refundable cash fee but also facilitated the return of capital to its shareholders, demonstrating the company's effective management of its resources and commitment to shareholder value. Through these initiatives, Forward Pharma continues to position itself as a key player in the biopharmaceutical industry, focusing on innovative solutions for complex health challenges.

Denmark

Forward Pharma A/S is a biopharmaceutical company that developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.

Forward Pharma

Company Details